Cargando…
Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention
BACKGROUND: The safety and efficacy profile of bivalirudin has not been examined in a randomised controlled trial of patients undergoing rescue PCI. OBJECTIVES: We conducted an open-label, multi-centre, randomised controlled trial to compare bivalirudin with heparin ± glycoprotein IIb/IIIa inhibitor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547635/ https://www.ncbi.nlm.nih.gov/pubmed/34699549 http://dx.doi.org/10.1371/journal.pone.0259148 |
_version_ | 1784590414955675648 |
---|---|
author | Faour, Amir Collins, Nicholas Williams, Trent Khan, Arshad Juergens, Craig P. Lo, Sidney Walters, Darren L. Chew, Derek P. French, John K. |
author_facet | Faour, Amir Collins, Nicholas Williams, Trent Khan, Arshad Juergens, Craig P. Lo, Sidney Walters, Darren L. Chew, Derek P. French, John K. |
author_sort | Faour, Amir |
collection | PubMed |
description | BACKGROUND: The safety and efficacy profile of bivalirudin has not been examined in a randomised controlled trial of patients undergoing rescue PCI. OBJECTIVES: We conducted an open-label, multi-centre, randomised controlled trial to compare bivalirudin with heparin ± glycoprotein IIb/IIIa inhibitors (GPIs) in patients undergoing rescue PCI. METHODS: Between 2010–2015, we randomly assigned 83 patients undergoing rescue PCI to bivalirudin (n = 42) or heparin ± GPIs (n = 41). The primary safety endpoint was any ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) bleeding at 90 days. The primary efficacy endpoint was infarct size measured by peak troponin levels as a multiple of the local upper reference limit (Tn/URL). Secondary endpoints included periprocedural change in haemoglobin adjusted for red cells transfused, TIMI (Thrombolysis in Myocardial Infarction) bleeding, ST-segment recovery and infarct size determined by the Selvester QRS score. RESULTS: The trial was terminated due to slow recruitment and futility after an interim analysis of 83 patients. The primary safety endpoint occurred in 6 (14%) patients in the bivalirudin group (4.8% GPIs) and 3 (7.3%) in the heparin ± GPIs group (54% GPIs) (risk ratio, 1.95, 95% confidence interval [CI], 0.52–7.3, P = 0.48). Infarct size was similar between the two groups (mean Tn/URL, 730 [±675] for bivalirudin, versus 984 [±1585] for heparin ± GPIs, difference, 254, 95% CI, -283-794, P = 0.86). There was a smaller decrease in the periprocedural haemoglobin level with bivalirudin than heparin ± GPIs (-7.5% [±15] versus -14% [±17], difference, -6.5%, 95% CI, -0.83–14, P = 0.0067). The rate of complete (≥70%) ST-segment recovery post-PCI was higher in patients randomised to heparin ± GPIs compared with bivalirudin. CONCLUSIONS: Whether bivalirudin compared with heparin ± GPI reduces bleeding in rescue PCI could not be determined. Slow recruitment and futility in the context of lower-than-expected bleeding event rates led to the termination of this trial (ANZCTR.org.au, ACTRN12610000152022). |
format | Online Article Text |
id | pubmed-8547635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-85476352021-10-27 Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention Faour, Amir Collins, Nicholas Williams, Trent Khan, Arshad Juergens, Craig P. Lo, Sidney Walters, Darren L. Chew, Derek P. French, John K. PLoS One Research Article BACKGROUND: The safety and efficacy profile of bivalirudin has not been examined in a randomised controlled trial of patients undergoing rescue PCI. OBJECTIVES: We conducted an open-label, multi-centre, randomised controlled trial to compare bivalirudin with heparin ± glycoprotein IIb/IIIa inhibitors (GPIs) in patients undergoing rescue PCI. METHODS: Between 2010–2015, we randomly assigned 83 patients undergoing rescue PCI to bivalirudin (n = 42) or heparin ± GPIs (n = 41). The primary safety endpoint was any ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) bleeding at 90 days. The primary efficacy endpoint was infarct size measured by peak troponin levels as a multiple of the local upper reference limit (Tn/URL). Secondary endpoints included periprocedural change in haemoglobin adjusted for red cells transfused, TIMI (Thrombolysis in Myocardial Infarction) bleeding, ST-segment recovery and infarct size determined by the Selvester QRS score. RESULTS: The trial was terminated due to slow recruitment and futility after an interim analysis of 83 patients. The primary safety endpoint occurred in 6 (14%) patients in the bivalirudin group (4.8% GPIs) and 3 (7.3%) in the heparin ± GPIs group (54% GPIs) (risk ratio, 1.95, 95% confidence interval [CI], 0.52–7.3, P = 0.48). Infarct size was similar between the two groups (mean Tn/URL, 730 [±675] for bivalirudin, versus 984 [±1585] for heparin ± GPIs, difference, 254, 95% CI, -283-794, P = 0.86). There was a smaller decrease in the periprocedural haemoglobin level with bivalirudin than heparin ± GPIs (-7.5% [±15] versus -14% [±17], difference, -6.5%, 95% CI, -0.83–14, P = 0.0067). The rate of complete (≥70%) ST-segment recovery post-PCI was higher in patients randomised to heparin ± GPIs compared with bivalirudin. CONCLUSIONS: Whether bivalirudin compared with heparin ± GPI reduces bleeding in rescue PCI could not be determined. Slow recruitment and futility in the context of lower-than-expected bleeding event rates led to the termination of this trial (ANZCTR.org.au, ACTRN12610000152022). Public Library of Science 2021-10-26 /pmc/articles/PMC8547635/ /pubmed/34699549 http://dx.doi.org/10.1371/journal.pone.0259148 Text en © 2021 Faour et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Faour, Amir Collins, Nicholas Williams, Trent Khan, Arshad Juergens, Craig P. Lo, Sidney Walters, Darren L. Chew, Derek P. French, John K. Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention |
title | Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention |
title_full | Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention |
title_fullStr | Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention |
title_full_unstemmed | Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention |
title_short | Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention |
title_sort | reperfusion after fibrinolytic therapy (raft): an open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547635/ https://www.ncbi.nlm.nih.gov/pubmed/34699549 http://dx.doi.org/10.1371/journal.pone.0259148 |
work_keys_str_mv | AT faouramir reperfusionafterfibrinolytictherapyraftanopenlabelmulticentrerandomisedcontrolledtrialofbivalirudinversusheparininrescuepercutaneouscoronaryintervention AT collinsnicholas reperfusionafterfibrinolytictherapyraftanopenlabelmulticentrerandomisedcontrolledtrialofbivalirudinversusheparininrescuepercutaneouscoronaryintervention AT williamstrent reperfusionafterfibrinolytictherapyraftanopenlabelmulticentrerandomisedcontrolledtrialofbivalirudinversusheparininrescuepercutaneouscoronaryintervention AT khanarshad reperfusionafterfibrinolytictherapyraftanopenlabelmulticentrerandomisedcontrolledtrialofbivalirudinversusheparininrescuepercutaneouscoronaryintervention AT juergenscraigp reperfusionafterfibrinolytictherapyraftanopenlabelmulticentrerandomisedcontrolledtrialofbivalirudinversusheparininrescuepercutaneouscoronaryintervention AT losidney reperfusionafterfibrinolytictherapyraftanopenlabelmulticentrerandomisedcontrolledtrialofbivalirudinversusheparininrescuepercutaneouscoronaryintervention AT waltersdarrenl reperfusionafterfibrinolytictherapyraftanopenlabelmulticentrerandomisedcontrolledtrialofbivalirudinversusheparininrescuepercutaneouscoronaryintervention AT chewderekp reperfusionafterfibrinolytictherapyraftanopenlabelmulticentrerandomisedcontrolledtrialofbivalirudinversusheparininrescuepercutaneouscoronaryintervention AT frenchjohnk reperfusionafterfibrinolytictherapyraftanopenlabelmulticentrerandomisedcontrolledtrialofbivalirudinversusheparininrescuepercutaneouscoronaryintervention |